We are on a mission to
outsmart cancer resistance.

Theseus is developing next-generation tyrosine kinase inhibitors (TKIs) to transform the way cancer is treated.

Learn Moredown

Our targeted, small molecule therapies are designed to address treatment-resistance in cancer.

Working to deliver best-in-class pan-variant tyrosine kinase inhibitors to cancer patients.

We are developing a pipeline of TKIs designed to inhibit all major cancer-causing and drug resistance mutations in clinically significant tyrosine kinase targets.